본 연구에서는 고지방식이(HFD)를 급식하여 제조한 비만마우스 모델을 사용하여 berberine (BBR)과 silibinin (SBN) 복합투여가 혈중 지질대사 및 항비만 개선 효능에 유의적인 시너지 효과가 있는지 조사하였다. HFD로 유도된 비만마우스를 8 주 동안 HFD의 지속적인 제공와 함께 BBR 및 SBN (BBR-SBN) 조합을 투여하였다. 실험이 진행되는 동안 체중과 식이량을 측정하였고 혈중 총 콜레스테롤, 중성지방 및 HDL 콜레스테롤 수준을 분석하였다. HFD를 제공한 마우스는 정상 대조군(NC) 그룹에 비해 체중과 총 콜레스테롤 및 중성지방 수치가 급격히 증가했다. 그러나 이러한 비만마우스에 BBR-SBN조합을 투여하였을 때 체중 증가가 현저하게 감소하였고 HDL 콜레스테롤 수치가 증가하였으며 총 콜레스테롤 및 중성지방 수치는 유의하게 억제되었다. HFD그룹의 복부지방 무게는 유의하게 증가했으며 부고환지방조직 내의 지방세포의 크기가 NC 그룹에 비해 크게 확장된 것으로 나타났다. 그러나 BBR-SBN 그룹에서는 지방세포의 크기가 NC 그룹의 크기와 비슷했으며 복부지방 무게가 현저하게 감소하였다. 더불어, HFD 그룹에서 보이는 간 조직의 거대 소포성 지방구의 축적은 BBR-SBN 그룹에서 크게 감소되었다. 이러한 결과는 BBR-SBN 조합이 HFD 유발 비만마우스에서 체중 및 복부 지방 증가를 현저하게 감소시키는 경향이 있으며 혈청 내의 총 콜레스테롤 및 중성지방 수준을 낮추어 항비만 효능을 개선시킬 수 있는 가능성을 보여주는 것으로 앞으로 항비만 치료 및 개선제제로서의 잠재력을 가지고 있음을 시사한다.
본 연구에서는 고지방식이(HFD)를 급식하여 제조한 비만마우스 모델을 사용하여 berberine (BBR)과 silibinin (SBN) 복합투여가 혈중 지질대사 및 항비만 개선 효능에 유의적인 시너지 효과가 있는지 조사하였다. HFD로 유도된 비만마우스를 8 주 동안 HFD의 지속적인 제공와 함께 BBR 및 SBN (BBR-SBN) 조합을 투여하였다. 실험이 진행되는 동안 체중과 식이량을 측정하였고 혈중 총 콜레스테롤, 중성지방 및 HDL 콜레스테롤 수준을 분석하였다. HFD를 제공한 마우스는 정상 대조군(NC) 그룹에 비해 체중과 총 콜레스테롤 및 중성지방 수치가 급격히 증가했다. 그러나 이러한 비만마우스에 BBR-SBN조합을 투여하였을 때 체중 증가가 현저하게 감소하였고 HDL 콜레스테롤 수치가 증가하였으며 총 콜레스테롤 및 중성지방 수치는 유의하게 억제되었다. HFD그룹의 복부지방 무게는 유의하게 증가했으며 부고환 지방조직 내의 지방세포의 크기가 NC 그룹에 비해 크게 확장된 것으로 나타났다. 그러나 BBR-SBN 그룹에서는 지방세포의 크기가 NC 그룹의 크기와 비슷했으며 복부지방 무게가 현저하게 감소하였다. 더불어, HFD 그룹에서 보이는 간 조직의 거대 소포성 지방구의 축적은 BBR-SBN 그룹에서 크게 감소되었다. 이러한 결과는 BBR-SBN 조합이 HFD 유발 비만마우스에서 체중 및 복부 지방 증가를 현저하게 감소시키는 경향이 있으며 혈청 내의 총 콜레스테롤 및 중성지방 수준을 낮추어 항비만 효능을 개선시킬 수 있는 가능성을 보여주는 것으로 앞으로 항비만 치료 및 개선제제로서의 잠재력을 가지고 있음을 시사한다.
In this study, we investigated whether the combined administration of berberine (BBR) and silibinin (SBN) was effective in improving hyperlipidemia and anti-obesity efficacy using a high-fat diet (HFD)-fed obese mouse model. HFD-induced obese mice were supplemented with the BBR and SBN combination (...
In this study, we investigated whether the combined administration of berberine (BBR) and silibinin (SBN) was effective in improving hyperlipidemia and anti-obesity efficacy using a high-fat diet (HFD)-fed obese mouse model. HFD-induced obese mice were supplemented with the BBR and SBN combination (BBR-SBN) along with the HFD administration for 8 weeks. During the experiment, body weight, food intake, and levels of total cholesterol, triglyceride and high-density lipoprotein (HDL)-cholesterol were analyzed. Consumption of HFD in the mice caused rapid increases in body weight and the levels of total cholesterol and triglycerides compared to the normal control (NC) group. However, supplementation of BBR-SBN in these obese mice significantly reduced body weight gain and suppressed the levels of total cholesterol and triglyceride with the increment of HDL cholesterol level. In the HFD-fed group, abdominal fat weight was significantly increased and the adipocytes within the epididymal adipose tissue were found to have expanded sizes compared to the NC group. However, in the BBR-SBN group, the sizes of the adipocytes were comparable to those of the NC group and abdominal fat weight was significantly reduced. Moreover, the deposition of giant vesicular fat cells in liver tissues seen in the HFD-fed group was considerably reduced in the BBR-SBN group. These results suggest that the BBR-SBN combination tends to have synergic potential as an anti-obesity agent by significantly reducing body weight gain as well as lowering serum lipid levels and thus improving anti-obesity efficacy in HFD-induced obese mice.
In this study, we investigated whether the combined administration of berberine (BBR) and silibinin (SBN) was effective in improving hyperlipidemia and anti-obesity efficacy using a high-fat diet (HFD)-fed obese mouse model. HFD-induced obese mice were supplemented with the BBR and SBN combination (BBR-SBN) along with the HFD administration for 8 weeks. During the experiment, body weight, food intake, and levels of total cholesterol, triglyceride and high-density lipoprotein (HDL)-cholesterol were analyzed. Consumption of HFD in the mice caused rapid increases in body weight and the levels of total cholesterol and triglycerides compared to the normal control (NC) group. However, supplementation of BBR-SBN in these obese mice significantly reduced body weight gain and suppressed the levels of total cholesterol and triglyceride with the increment of HDL cholesterol level. In the HFD-fed group, abdominal fat weight was significantly increased and the adipocytes within the epididymal adipose tissue were found to have expanded sizes compared to the NC group. However, in the BBR-SBN group, the sizes of the adipocytes were comparable to those of the NC group and abdominal fat weight was significantly reduced. Moreover, the deposition of giant vesicular fat cells in liver tissues seen in the HFD-fed group was considerably reduced in the BBR-SBN group. These results suggest that the BBR-SBN combination tends to have synergic potential as an anti-obesity agent by significantly reducing body weight gain as well as lowering serum lipid levels and thus improving anti-obesity efficacy in HFD-induced obese mice.
Aviva M, Jennifer S, Eugenie HC, Alison EF, Graham C, William HD (1999) The disease burden associated with overweight and obesity. J Am Med Assoc 282: 1523-1529. doi: 10.1001/jama.282.16.1523
Korea Disease Control and Prevention Agency, Health and Nutrition Survey Analysis Division (2020) Announcement of the results of the 8th year 1st national health and nutrition survey: 26-27
Gregory JW (2019) Prevention of obesity and metabolic syndrome in children. Front Endocrinol 10: 669. doi: 10.3389/fendo.2019.00669
Janes PJ, Leith CA, Pederson RA (1993) Meal-frequency effects on plasma hormone concentrations and cholesterol synthesis in human. Am J Clin Nutr 57: 868-874. doi: 10.1093/ajcn/57.6.868
Anderson JW, Spencer DB, Hamilton CC, Smith SF, Tietyen J, Bryant CA, Oeltgen P (1990) Oat-bran cereal lowers serum total and LDL cholesterol in hypercholesterolemic men. Am J Clin Nutr 52: 495-499. doi: 10.1093/ajcn/52.3.495
Farnier M, Davignon J (1998) Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82(4B): 3J-10J. doi: 10.1016/s0002-9149(98)00423-8
Choi HJ, Park JN (2004) Management of risk of statin therapy. J Kor Acad Fam Med 25: 713-720
Kim Y, Choi NK, Kim YJ, Park KH, Park BJ (2010) Liver injury incidence and risk after statin use. J Pharmacoepidemiol Risk Mngmt 3: 64-73
Kim KH, Ahn SC, Lee MS, Kweon OS, Oh WK, Kim MS, Sohn CB, Ahn JS (2003) Adipocyte differentiation inhibitor isolated from the barks of Phellodendron amurense. Korean J Food Sci Technol 35: 503-509
Lee JW, Kang YJ, Choi HK, Yoon YG (2018) Fractionated Coptis chinensis extract and its bioactive component suppress Propionibacterium acnes-stimulated inflammation in human keratinocytes. J Microbiol Biotechnol 28: 839-848. doi: 10.4014/jmb.1712.12051
Kim HP, Yoon YG (2018) The protective effect of berberine on Propionibacterium acnes-induced inflammatory response in human monocytes. J Appl Biol Chem 61: 181-186. doi: 10.3839/jabc.2018.026
Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, Jiang JD (2009) Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 58: 109-119. doi: 10.1016/j.metabol.2008.08.013
Li Z, Jiang JD, Kong WJ (2014) Berberine up-regulates hepatic low density lipoprotein receptor through Ras-independent but AMP activated protein kinase-dependent Raf-1 activation. Biol Pharm Bull 37:1766-1775. doi: 10.1248/bpb.b14-00412
Dong B, Li H, Singh AB, Cao A, Liu J (2015) Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1a protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem 290: 4047-4058. doi: 10.1074/jbc.M114.597229
Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 48: 646-654. doi: 10.1002/hep.22354
Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X (2014) Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism 63: 1167-1177. doi: 10.1016/j.metabol.2014.05.013
Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X, Zhou L (2015) Berberine suppresses adipocyte differentiation via decreasing CREB transcriptional activity. PLoS One 10: e0125667. doi: 10.1371/journal.pone.0125667
Zhu X, Yang J, Zhu W, Yin X, Yang B, Wei Y, Guo X (2018) Combination of berberine with resveratrol improves the lipid-lowering efficacy. Int J Mol Sci 19: 3903. doi: 10.3390/ijms19123903
Abenavoli L, Izzo AA, Milic N, Cicala C, Santini A, Capasso R (2018) Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 32: 2202-2213. doi: 10.1002/ptr.6171
Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 17: 2288-2301. doi: 10.3748/wjg.v17.i18.2288
Yun DG, Lee DG (2017) Assessment of silibinin as a potential antifungal agent and investigation of its mechanism of action. IUBMB Life 69: 631-637. doi: 10.1002/iub.1647
Suh HJ, Cho SY, Kim EY, Choi HS (2015) Blockade of lipid accumulation by silibinin in adipocytes and zebrafish. Chem Biol Interact 227: 53-62. doi: 10.1016/j.cbi.2014.12.027
Lee SG, Kwon TK, Nam JO (2017) Silibinin inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Microbiol Biotechnol Lett 45: 27-34. doi: 10.4014/mbl.1610.10005
Ramanathan R, Sivanesan K (2017) Evaluation of ameliorative ability of silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: Role of Silibinin in Phase I and II drug metabolism. Chem-Biol Interact 273: 142-153
Kunutsor SK, Apekey TA, Seddoh D, Walley J (2014) Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 43: 187-201. doi: 10.1093/ije/dyt192
Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M (2015) Silybum marianum: beyond hepatoprotection. J Evid Based Compl Alt Med 20: 292-301. doi: 10.1177/2156587215571116
Hwang KH, Ahn JY, Kim SA, Ha TY (2009) Anti-obesity effect of berberine in mice fed a high fat diet. J Food Sci Nutr 14: 298-302. doi: 10.3746/jfn.2009.14.4.298
Koo HJ, Kang SC, Jang SA, Kwon JE, Sohn E, Sohn EH (2014) Effects of protocatechuic acid derived from Rubus coreanus on the lipid metabolism in high cholesterol diet-induced mice. Korean J Plant Res 27: 271-278. doi: 10.7732/kjpr.2014.27.4.271
Kim JY, Shin M, Heo YR (2014) Effects of stabilized rice bran on obesity and antioxidative enzyme activity in high fat diet-induced obese C57BL/6 mice. Korean Soc Food Sci Nutr 43: 1148-1157. doi: 10.3746/jkfn.2014.43.8.1148
Lee KS, Kim HP, Park HJ, Yoon YG (2021) Improvement of testosterone deficiency by fermented Momordica charantia extracts in aging male rats. Food Sci Biotechnol 30: 443-454. doi: 10.1007/s10068-020-00872-x
Hong SB, Shin KA (2018) Significance of non HDL-cholesterol and triglyceride to HDL-cholesterol ratio as predictors for metabolic syndrome among korean elderly. Korean J Clin Lab Sci 50: 245-252. doi: 10.15324/kjcls.2018.50.3.245
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.